Purple Biotech (PPBT)
(Real Time Quote from BATS)
$0.55 USD
-0.01 (-2.33%)
Updated May 21, 2024 01:16 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Purple Biotech Ltd. Sponsored ADR [PPBT]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
4Q23 Recap: CM24 Phase 2 Interim Data and NT219 Phase 2 Initiation Expected 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
NT219 Dose Escalation Data Presented at ESMO TAT Show Encouraging Activity
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
NT219 to Advance Into Phase 2 With 100 mg/kg Dose For Treatment of SCCHN
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
3Q23 Recap: CM24 Interim Data Expected in 1H24; NT219 Early Efficacy Data Are Encouraging
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
2Q23 Recap: Timelines Remain on Track With Data Updates Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
1Q23 Recap: NT219 and CM24 Studies to Have Data Updates in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
4Q22 Take: Pipeline Progress Continues With Data Updates For CM24 and NT219 Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
3Q22 Take: Catalysts Across the Pipeline Expected Throughout 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
First-in-Class Assets for Difficult to Treat Solid Tumors; Initiating at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Name Change to Purple Biotech Ltd.; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|